Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 plus fulvestrant versus fulvestrant in ER-positive, HER2-negative metastatic breast cancer after aromatase inhibitor progression
2014-003220-52Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2015
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing CC-486 + fulvestrant with Fulvestrant monotherapy (2 arms). Primary endpoint: Progression-free survival hazard ratio. Started Jan 2015; status: completed.
02
Drugs
CC-486fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-003220-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003220-52.